Navigation Links
Union Members Hold Demonstrations at Philadelphia Nursing Home
Date:9/19/2007

Union alleges racially insensitive and hostile work environment.

PHILADELPHIA, Sept. 19 /PRNewswire-USNewswire/ -- Leaders and members of AFSCME District Council 33, Local 488, held two demonstrations today at Fairmount Long Term Care/Philadelphia Nursing Home, located at 2100 West Girard Avenue. The first demonstration was held at 6:30 a.m. and the second one was held at 2:30 p.m.

Tensions among workers at the Philadelphia Nursing Home continue to intensify in the face of management's failure to take appropriate action to address the racially insensitive conduct of one of its managers. The Union representing the workers has filed charges with the Human Relations Commission.

AFSCME Local 488 Business Manager Evon Sutton said: "Management's failure to redress what the workers perceive to be a racially insensitive and hostile work environment directly interferes with the mission of the workers, and frustrates a dedicated workforce that deserves better."

The triggering incident occurred on August 2, 2007, when a Unit Manager posted a cartoon of a monkey with the legend: "Stand tall, reach for the stars, and always use deodorant."

The cartoon was placed on a bulletin board in an employee locker room. The document incensed the predominantly African-American workforce. The PNH investigation confirmed the identity of the Unit Manager, a Caucasian, as the responsible party. However, no disciplinary action has been imposed.

According to Sutton, PNH's lack of response represents a double standard. "In every case in which an hourly worker is charged with misconduct," Sutton said, "the employee involved is immediately suspended pending an investigation. In this case, management took absolutely no action, despite confirmation of the allegation."

The hourly workforce has engaged in demonstrations and the Union has suggested that Management, at minimum, reassign the Unit Manager, to provide the parties some relief.

Mem
'/>"/>

SOURCE AFSCME Local 488
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Nanotechnology Revolution To Be Spearheaded By European Union
2. Slovenia, Bulgaria, Greece Face Bird Flu Threat: European Union
3. Heart Brakes: Hearts in European Union Invite Health Attention
4. French Minister To Visit La Reunion Island To Monitor Chikungunya Epidemic
5. ‘Drug Resistant TB’ Rattles the Union Ministy
6. European Union: Poultry producers Need Aid to Survive Bird flu crisis
7. African Union Launches A Programme On Acceleration of HIV Prevention
8. Union Health Minister visits chikungunya-hit areas in Kerala
9. Union Budget: Impact on Health Sector
10. Scary Spice Shedding Weight for Reunion Tour
11. Trade Unionists Join Polish Nurses Protest
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Helix BioPharma Reports On 2009 Annual General Meeting 2Helix BioPharma Reports On 2009 Annual General Meeting 3NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 2Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 3Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 4Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 5Undocumented Hispanics Face Health Care Roadblocks in U S 60405 1Undocumented Hispanics Face Health Care Roadblocks in U S 60405 2U S President 26apos 3Bs Emergency Plan for AIDS Relief Joins mHealth Alliance 60401 1U S President 26apos 3Bs Emergency Plan for AIDS Relief Joins mHealth Alliance 60401 2U S President 26apos 3Bs Emergency Plan for AIDS Relief Joins mHealth Alliance 60401 3Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival 14666 1Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival 14666 2Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival 14666 3Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival 14666 4